NCT00003590

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

Phase II Study of Hydroxyurea for Unresectable Meningioma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: SWOG Cancer Research Network · Network
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.

Detailed description

OBJECTIVES: * Determine the partial and complete response rates in patients with unresectable benign meningioma treated with hydroxyurea. * Assess the quantitative and qualitative toxic effects of this drug in this patient population. OUTLINE: Patients receive oral hydroxyurea twice daily for 2 years in the absence of disease progression or unacceptable toxicity. Patients are followed at 3 months, 6 months, and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 38 patients will be accrued for this study within 13 months.

Conditions

• Adult Meningioma

Interventions

Type	Name	Description
DRUG	hydroxyurea	20 mg/kg/day PO

Timeline

• Start date: 1998-11-01
• Primary completion: 2008-12-01
• Completion: 2011-07-01
• First posted: 2003-01-27
• Last updated: 2016-05-20
• Results posted: 2012-02-16

Locations

133 sites across 1 country: United States